l General Information |
Product Name | Anagrelide Hydrochloride |
General description | Anagrelide Hydrochloride is an antithrombotic and platelet reducing agent that is used to treat the thrombocythemia associated with myeloproliferative diseases. |
Synonym | 6,7-Dichloro-1,5-dihydro-imidazo[2,1-b]quinazolin-2(3H)-one hydrochloride |
Purity | ≥98%(HPLC) | CAS Number | 58579-51-4 |
Formula | C10H7Cl2N3O · HCl | Molecular Weight | 292.55 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or Off-white solid |
Solubility(25℃) | DMSO | ≥10mg/mL |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Anagrelide Hydrochloride is the hydrochloride salt of a synthetic quinazoline derivative, Anagrelide Hydrochloride reduces platelet production through a decrease in megakaryocyte maturation. Anagrelide inhibits cyclic AMP phosphodiesterase, as well as ADP- and collagen-induced platelet aggregation. At therapeutic doses, it does not influence white cell counts or coagulation parameters. Anagrelide is used for treatment of essential thrombocythemia to reduce elevated platelet counts and the risk of thrombosis. |
Application | 1. Fibrinolytic Agents 2. Platelet Aggregation Inhibitors |
l Packaging & Storage |
Packaging | 50mg; 250mg |
Storage temp. | 0-5℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
